Literature DB >> 26927444

Cytomegalovirus (CMV) Monitoring After Liver Transplantation: Comparison of CMV Pp65 Antigenemia Assay with Real-Time PCR Calibrated to WHO International Standard.

Hideya Kamei1, Yoshinori Ito2, Yasuharu Onishi1, Michio Suzuki2, Hisashi Imai1, Nobuhiko Kurata1, Tomohide Hori1, Takahisa Tainaka3, Hiroo Uchida3, Yasuhiro Ogura1.   

Abstract

BACKGROUND: Cytomegalovirus (CMV) remains a major cause of morbidity and mortality for liver transplant recipients. Although the CMV pp65 antigenemia (AG) assay has been widely used to monitor patients for CMV infection after liver transplantation, real-time PCR is becoming the standard procedure. The World Health Organization (WHO) International Reference Standard for CMV quantification has become available to standardize values diagnostic of CMV infection.
MATERIAL AND METHODS: Our in-house real-time PCR assay was standardized using the WHO standard reagents. Levels of CMV DNA in 1339 blood samples obtained from 190 liver transplant recipients were quantified and expressed in international units, and results were then compared with those of the CMV pp65 AG assay performed on the same blood samples. Correlation was assessed and receiver operating characteristic curves were analyzed to determine the optimal cut-off value for CMV DNA (IU/mL) PCR results.
RESULTS: Significant correlation was found between results of the 2 assay methods (p<0.001, r=0.715); a PCR result of ≥288 IU/mL predicted a positive result by the CMV AG assay (1 positive cells/150 000 leukocytes) with a sensitivity of 67.4% and specificity of 94.8%.
CONCLUSIONS: To the best of our knowledge, this is the first report to compare CMV AG and real-time PCR (calibrated to the WHO standard) results in a large number of recipients after liver transplantation. Use of this technique may provide useful information for the management of CMV infection.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26927444     DOI: 10.12659/aot.895677

Source DB:  PubMed          Journal:  Ann Transplant        ISSN: 1425-9524            Impact factor:   1.530


  6 in total

Review 1.  Intestinal perforation due to hemorrhagic Cytomegalovirus enteritis in a patient with severe uncontrolled lupus nephritis: a case and review of the literature.

Authors:  Keigo Ikeda; Shihoko Nakajima; Kana Tanji; Takuya Hirai; Kaori Uomori; Shinji Morimoto; Shigeki Tomita; Masaki Fukunaga; Naoto Tamura; Iwao Sekigawa
Journal:  Rheumatol Int       Date:  2017-03-11       Impact factor: 2.631

2.  Detection of Cytomegalovirus (CMV) Infection in Wheezing Infants by Urine DNA and Serum IgG Testing.

Authors:  Zhao-Cheng Zeng; Qing Chang; Zhi-Wei Sun; Ming-Mei Song; Xin-Ling Jin; Shu-Ya Jiang; Xia Yang
Journal:  Med Sci Monit       Date:  2017-03-11

3.  Cytomegalovirus antigenemia in patients with autoimmune and non-autoimmune diseases in Beijing: A 10-year single hospital experience.

Authors:  Jingtao Cui; Wenjuan Yan; Hongjie Xie; Shaoxia Xu; Qiaofeng Wang; Weihong Zhang; Anping Ni
Journal:  PLoS One       Date:  2019-08-28       Impact factor: 3.240

4.  Transition from antigenemia to quantitative nucleic acid amplification testing in cytomegalovirus-seropositive kidney transplant recipients receiving preemptive therapy for cytomegalovirus infection.

Authors:  Mônica Rika Nakamura; Lúcio R Requião-Moura; Roberto Mayer Gallo; Camila Botelho; Júlia Taddeo; Laila Almeida Viana; Cláudia Rosso Felipe; José Medina-Pestana; Hélio Tedesco-Silva
Journal:  Sci Rep       Date:  2022-07-27       Impact factor: 4.996

5.  Clinical validation of an in-house quantitative real time PCR assay for cytomegalovirus infection using the 1st WHO International Standard in kidney transplant patients.

Authors:  Cassia F B Caurio; Odelta S Allende; Roger Kist; Kênya L Santos; Izadora C S Vasconcellos; Franciéli P Rozales; Daiane F Dalla Lana; Bruno M Praetzel; Ana Paula Alegretti; Alessandro C Pasqualotto
Journal:  J Bras Nefrol       Date:  2021 Oct-Dec

6.  Clinical correlates of pp65 antigenemia monitoring in the first months of post kidney transplant in patients undergoing universal prophylaxis or preemptive therapy.

Authors:  Fabiana Rabe Carvalho; Rachel Ingrid Juliboni Cosendey; Cintia Fernandes Souza; Thalia Medeiros; Paulo Alexandre Menezes; Andrea Alice Silva; Jorge Reis Almeida; Jocemir Ronaldo Lugon
Journal:  Braz J Infect Dis       Date:  2016-11-23       Impact factor: 3.257

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.